Quantx Biosciences closed an oversubscribed $85 million Series B to advance two oral immunology programs into the clinic: a STAT6 small‑molecule inhibitor and an IL‑17 oral inhibitor. The company said proceeds will fund IND‑enabling studies and early clinical development while leveraging its computational drug‑discovery platform that blends physics‑based and statistical modeling. Quantx co‑founders highlighted the firm’s platform as enabling rapid hit‑to‑lead cycles and the financing positions the company to initiate first‑in‑human studies for both programs. Investors cited the need for differentiated oral immunology agents with potential to address chronic inflammatory diseases.